Scorpion Capital
Tracked across 3 events · 194 articles · First seen Mar 07, 2026 · Last active Apr 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Regulatory
Scorpion Capital published a 415-page report alleging issues with Soleno Therapeutics' drug DCCR, which triggered a significant decline in Soleno's stock price and subsequent legal investigations.
Mar 10, 2026 · 7 articles
Regulatory
Scorpion Capital LLC published a critical report on Soleno Therapeutics' DCCR and its Phase 3 clinical trial program, alleging the drug was worthless and toxic. This report contributed to a nearly 12% decline in Soleno Therapeutics' stock price.
Mar 07, 2026 · 7 articles
Regulatory
Scorpion Capital, an activist short seller, published a report raising questions about Soleno Therapeutics' disclosures regarding VYKAT™ XR, alleging safety concerns and irregularities in trial data. This report contributed to a significant drop in Soleno's stock price.
Mar 09, 2026 · 180 articles
Soleno Therapeutics
critic of
↔
Scorpion Capital
Scorpion Capital published a critical report on Soleno Therapeutics and its drug
NEWSDESK
Track Scorpion Capital live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard